Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
J Am Geriatr Soc. 2022 Jun;70(6):1664-1672. doi: 10.1111/jgs.17752. Epub 2022 Mar 18.
Cognitive function is essential to effective self-management of heart failure (HF). Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) can coexist with HF, but its exact prevalence and impact on health care utilization and death are not well defined.
Residents from 7 southeast Minnesota counties with a first-ever diagnosis code for HF between January 1, 2013 and December 31, 2018 were identified. Clinically diagnosed AD/ADRD was ascertained using the Centers for Medicare and Medicaid (CMS) Chronic Conditions Data Warehouse algorithm. Patients were followed through March 31, 2020. Cox and Andersen-Gill models were used to examine associations between AD/ADRD (before and after HF) and death and hospitalizations, respectively.
Among 6336 patients with HF (mean age [SD] 75 years [14], 48% female), 644 (10%) carried a diagnosis of AD/ADRD at index HF diagnosis. The 3-year cumulative incidence of AD/ADRD after HF diagnosis was 17%. During follow-up (mean [SD] 3.2 [1.9] years), 2618 deaths and 15,475 hospitalizations occurred. After adjustment, patients with AD/ADRD before HF had nearly a 2.7 times increased risk of death, but no increased risk of hospitalization compared to those without AD/ADRD. When AD/ADRD was diagnosed after the index HF date, patients experienced a 3.7 times increased risk of death and a 73% increased risk of hospitalization compared to those who remain free of AD/ADRD.
In a large, community cohort of patients with incident HF, the burden of AD/ADRD is quite high as more than one-fourth of patients with HF received a diagnosis of AD/ADRD either before or after HF diagnosis. AD/ADRD markedly increases the risk of adverse outcomes in HF underscoring the need for future studies focused on holistic approaches to improve outcomes.
认知功能对于心力衰竭(HF)的有效自我管理至关重要。阿尔茨海默病和阿尔茨海默病相关痴呆(AD/ADRD)可与 HF 共存,但确切的患病率及其对医疗保健利用和死亡的影响尚未明确界定。
从 2013 年 1 月 1 日至 2018 年 12 月 31 日期间,在明尼苏达州东南部的 7 个县中首次诊断出 HF 的居民中识别出患者。使用医疗保险和医疗补助服务中心(CMS)慢性病数据仓库算法确定临床诊断的 AD/ADRD。通过 2020 年 3 月 31 日对患者进行随访。使用 Cox 和 Andersen-Gill 模型分别检查 AD/ADRD(HF 之前和之后)与死亡和住院之间的关联。
在 6336 例 HF 患者(平均年龄[标准差]75 岁[14],48%为女性)中,644 例(10%)在 HF 诊断时患有 AD/ADRD。HF 诊断后 3 年的 AD/ADRD 累积发生率为 17%。在随访期间(平均[标准差]3.2[1.9]年),发生了 2618 例死亡和 15475 例住院。调整后,HF 前患有 AD/ADRD 的患者死亡风险几乎增加了 2.7 倍,但与无 AD/ADRD 的患者相比,住院风险无增加。当 AD/ADRD 在指数 HF 日期后诊断时,与那些仍然没有 AD/ADRD 的患者相比,患者的死亡风险增加了 3.7 倍,住院风险增加了 73%。
在一项针对新发 HF 患者的大型社区队列研究中,AD/ADRD 的负担相当高,超过四分之一的 HF 患者在 HF 诊断之前或之后被诊断为 AD/ADRD。AD/ADRD 显著增加了 HF 的不良预后风险,这凸显了未来需要进行关注整体方法的研究,以改善预后。